SCANDINAVIAN CHEMOTECH AB Scandinavian ChemoTech AB Share Price
Equities
CMOTEC B
SE0009242654
Advanced Medical Equipment & Technology
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.15 SEK | -4.02% |
|
-2.27% | -20.37% |
| Sales 2023 | 2.82M 259K 20.63M | Sales 2024 * | 5M 458K 36.55M | Capitalization | 40.18M 3.68M 294M |
|---|---|---|---|---|---|
| Net income 2023 | -21M -1.92M -154M | Net income 2024 * | -19M -1.74M -139M | EV / Sales 2023 | 15.6 x |
| Net Debt 2023 * | 4M 366K 29.24M | Net cash position 2024 * | 6.2M 568K 45.33M | EV / Sales 2024 * | 6.8 x |
| P/E ratio 2023 |
-1.73
x | P/E ratio 2024 * |
-3.2
x | Employees | 6 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 62.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on Scandinavian ChemoTech AB
More press releases
| 1 day | -4.02% | ||
| 1 week | -2.27% | ||
| Current month | +2.38% | ||
| 1 month | -0.46% | ||
| 3 months | -36.01% | ||
| 6 months | -10.79% | ||
| Current year | -20.37% |
1 week
2.05
2.66
1 month
2.002.99
Current year
1.765.20
1 year
1.645.38
3 years
1.6441.00
5 years
1.6441.00
10 years
1.6484.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 50 | 31/12/14 | |
Ann Ohlsson
DFI | Director of Finance/CFO | 58 | - |
Suhail Mufti
CTO | Chief Tech/Sci/R&D Officer | - | 05/10/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robin Sukhia
CHM | Chairman | 51 | 31/12/19 |
| Director/Board Member | 71 | 31/12/19 | |
| Director/Board Member | 71 | 31/12/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 2.15 | -4.02% | 1 779 |
| 26/04/24 | 2.24 | -1.32% | 2,900 |
| 25/04/24 | 2.27 | -1.30% | 14,938 |
| 24/04/24 | 2.3 | +5.02% | 4,950 |
| 23/04/24 | 2.19 | -0.45% | 4,835 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 08:48 am
More quotes
Scandinavian ChemoTech AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused on cancer treatment and manufactures specialized medical equipment. The Company's product IQWave is an electrochemotherapy (ECT) device. The IQWave system enhances the effects of the chemotherapeutic substance by opening up small pores in the tumor cells, giving the injected chemotherapeutic substance (no more than 15 IU of bleomycin) direct access to the DNA of the target cells. Among the product's applications are hypernephroma, kaposi sarcoma, transitional cell carcinoma, head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma. The treatment can be used for cutaneous as well as subcutaneous tumors.
Calendar
13/05/2024
- Q1 2024 Earnings Release
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.37% | 3.66M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +2.28% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- CMOTEC B Stock
